Dianthus Therapeutics, Inc. (DNTH)
- Previous Close
21.70 - Open
21.93 - Bid 21.51 x 200
- Ask 21.94 x 200
- Day's Range
21.56 - 22.14 - 52 Week Range
13.37 - 32.27 - Volume
150,873 - Avg. Volume
346,470 - Market Cap (intraday)
697.132M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.55 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
52.60
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
dianthustx.comRecent News: DNTH
View More
Performance Overview: DNTH
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNTH
View MoreValuation Measures
Market Cap
697.13M
Enterprise Value
423.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
115.94
Price/Book (mrq)
1.98
Enterprise Value/Revenue
67.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.01%
Return on Equity (ttm)
-32.60%
Revenue (ttm)
6.24M
Net Income Avi to Common (ttm)
-84.97M
Diluted EPS (ttm)
-2.55
Balance Sheet and Cash Flow
Total Cash (mrq)
275.24M
Total Debt/Equity (mrq)
0.42%
Levered Free Cash Flow (ttm)
-43.48M